Vertex Pharmaceuticals (VRTX) Net Margin (2009 - 2026)

Vertex Pharmaceuticals' Net Margin history runs 17 years deep, the most recent figure standing at 34.53% for Q1 2026.

• On a quarterly basis, Net Margin rose 1120.0% year-over-year to 34.53% in Q1 2026; TTM through Mar 2026 was 35.51%, a 4442.0% increase from a year earlier, with the FY2025 full-year figure at 32.94%, up 3780.0% from the prior year.
• Net Margin slipped to 34.53% in Q1 2026 per VRTX's latest filing, from 37.34% in the prior quarter.
• Across five years, Net Margin topped out at 41.69% in Q3 2023 and bottomed at 135.83% in Q2 2024.
• The 5-year median for Net Margin is 36.33% (2022), against an average of 25.55%.
• Across the five-year window, Net Margin tumbled 17256 bps in 2024 and soared 17067 bps in 2025, its largest moves.
• Year by year, Net Margin stood at 35.56% in 2022, then advanced by 8 bps to 38.48% in 2023, then fell by 19 bps to 31.35% in 2024, then grew by 19 bps to 37.34% in 2025, then declined by 8 bps to 34.53% in 2026.
• Per Business Quant, the three latest VRTX Net Margin figures stand at 34.53% (Q1 2026), 37.34% (Q4 2025), and 35.2% (Q3 2025).